Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics – Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...